KMT2C (Q8NEZ4) variants and mutations
KMT2C (also known as Q8NEZ4) is a human protein-coding gene encoding a histone-lysine N-methyltransferase 2C protein. It helps establish enhancer-associated H3K4 methylation and thereby controls lineage-specific transcription together with other COMPASS-family proteins. Somatic loss-of-function alterations are frequent across cancers, while germline variants can cause neurodevelopmental phenotypes. This analysis covers 15,046 KMT2C variants and mutations. Of these, 36% have computational variant effect predictions. Disease context includes Kleefstra syndrome 2, prostate adenocarcinoma, and Intellectual disability. Example KMT2C variants include M1?, S2A, and S2L.
Variant analysis overview
- Gene: KMT2C
- Protein: Q8NEZ4
- UniProt accession: Q8NEZ4
- Organism: Homo sapiens
- Variants analyzed: 15046
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 14,899 unspecified-consequence records; 3 stop lost; 45 missense variants; 4 stop-gained variants; 1 frameshift variants; 81 synonymous variants; 3 in-frame insertions; 2 in-frame deletions; 5 splice-region variants; 3 substitution
- Prediction scores: 5,347 variants have prediction scores (36% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: Kleefstra syndrome 2, prostate adenocarcinoma, Intellectual disability, medulloblastoma, cervical squamous cell carcinoma, breast adenocarcinoma, hereditary disease, urinary bladder cancer, pancreatic adenocarcinoma, salivary gland carcinoma, pilocytic astrocytoma, Kleefstra syndrome due to a point mutation.
Protein structure and variant hotspots
- Protein features: 5 domains; 6 binding sites; 24 post-translational modification sites.
- Structural context: 808 variants have structural context.
- PTM context: 88 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable KMT2C variants
Examples include M1?, S2A, S2L, S2P, S2W, S3*, S3A, S3L. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1?, NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- S2A (p.Ser2Ala), Ensembl rs1362257174
- S2L (p.Ser2Leu), 1000Genomes rs556229991, ExAC rs556229991, gnomAD rs556229991, REVEL 0.46, CADD 25.60
- S2P (p.Ser2Pro), Ensembl rs1362257174, REVEL 0.47, CADD 25.40
- S2W (p.Ser2Trp), 1000Genomes rs556229991, ExAC rs556229991, gnomAD rs556229991
- S3* (p.Ser3Ter), gnomAD rs1281367709, CADD 35.00
- S3A (p.Ser3Ala), Ensembl rs2097912165, REVEL 0.24, CADD 23.00
- S3L (p.Ser3Leu), gnomAD rs1281367709, REVEL 0.29, CADD 23.40
- S3P (p.Ser3Pro), Ensembl rs2097912165, REVEL 0.21, CADD 23.30
- S3T (p.Ser3Thr), Ensembl rs2097912165
- S3W (p.Ser3Trp), NCI-TCGA TCGA novel, gnomAD rs1281367709, Variant assessed as somatic; moderate impact.
- E4* (p.Glu4Ter), gnomAD rs1307138056, CADD 35.00
- E4A (p.Glu4Ala), gnomAD rs1430028387, REVEL 0.32, CADD 24.60
- E4G (p.Glu4Gly), gnomAD rs1430028387, REVEL 0.33, CADD 26.50
- E5D (p.Glu5Asp), Ensembl rs1590054258, REVEL 0.36, CADD 23.90
- E5G (p.Glu5Gly), gnomAD rs1345919106, REVEL 0.34, CADD 26.30
- E5K (p.Glu5Lys), cosmic curated COSV51441, TOPMed rs1002542913, REVEL 0.37, CADD 24.80
- E5Q (p.Glu5Gln), TOPMed rs1002542913
- E5V (p.Glu5Val), gnomAD rs1345919106, REVEL 0.43, CADD 25.20
- D6A (p.Asp6Ala), Ensembl rs2116822073
- D6E (p.Asp6Glu), TOPMed rs1384359152, gnomAD rs1384359152, REVEL 0.33, CADD 22.90
- D6G (p.Asp6Gly), Ensembl rs2116822073, REVEL 0.41, CADD 24.00
- D6H (p.Asp6His), Ensembl rs2116822090, REVEL 0.40, CADD 24.60
- K7N (p.Lys7Asn), Ensembl rs2116822062, REVEL 0.20, CADD 22.30
- K7R (p.Lys7Arg), cosmic curated COSV51483, gnomAD rs1317128032, REVEL 0.21, CADD 16.80
- S8G (p.Ser8Gly), Ensembl rs2116822058, REVEL 0.35, CADD 23.20
- S8N (p.Ser8Asn), TOPMed rs1398617617, gnomAD rs1398617617, REVEL 0.36, CADD 22.20, Uncertain significance
- S8R (p.Ser8Arg), TOPMed rs1293115440, REVEL 0.37, CADD 22.60
- S8T (p.Ser8Thr), rs1398617617, ClinGen CA370104672, ClinVar RCV002462562, TOPMed rs1398617617, REVEL 0.32, CADD 17.80, Uncertain significance, not provided
- V9E (p.Val9Glu), cosmic curated COSV51472, Ensembl rs2116822033
- V9G (p.Val9Gly), Ensembl rs2116822033
- V9M (p.Val9Met), NCI-TCGA Cosmic COSV1000, cosmic curated COSV10007, NCI-TCGA Cosmic COSV5152, REVEL 0.26, CADD 19.50, Variant assessed as somatic; moderate impact.
- E10* (p.Glu10Ter), gnomAD rs1590054120, CADD 36.00, Uncertain significance
- E10D (p.Glu10Asp), rs1386734027, ClinGen CA370104628, ClinVar RCV002470633, gnomAD rs1386734027, REVEL 0.29, CADD 17.90, Uncertain significance, Kleefstra syndrome 2
- E10G (p.Glu10Gly), cosmic curated COSV10726, Ensembl rs2116822001, REVEL 0.27, CADD 23.50
- E10K (p.Glu10Lys), rs1590054120, ClinGen CA370104647, cosmic curated COSV51472, ClinVar RCV003229989, REVEL 0.23, CADD 21.80, Uncertain significance, not provided
- E10Q (p.Glu10Gln), gnomAD rs1590054120, Uncertain significance, Kleefstra syndrome 2
- Q11* (p.Gln11Ter), cosmic curated COSV51482, Ensembl rs2116821988, CADD 35.00
- Q11H (p.Gln11His), TOPMed rs1158616344, gnomAD rs1158616344, REVEL 0.21, CADD 22.50
- Q11L (p.Gln11Leu), Ensembl rs2097911950
- Q11P (p.Gln11Pro), Ensembl rs2097911950
- Q11R (p.Gln11Arg), Ensembl rs2097911950, REVEL 0.20, CADD 22.50
- P12L (p.Pro12Leu), TOPMed rs1427808282, gnomAD rs1427808282, REVEL 0.26, CADD 22.60
- P12R (p.Pro12Arg), TOPMed rs1427808282, gnomAD rs1427808282, REVEL 0.22, CADD 22.40
- P12S (p.Pro12Ser), cosmic curated COSV51504, gnomAD rs1468886245, REVEL 0.16, CADD 20.30, Uncertain significance, not specified
- Q13* (p.Gln13Ter), 1000Genomes rs570689281, gnomAD rs570689281, CADD 35.00
- Q13H (p.Gln13His), Ensembl rs2097911845, REVEL 0.24, CADD 22.00
- Q13P (p.Gln13Pro), TOPMed rs866392536, gnomAD rs866392536, REVEL 0.26, CADD 19.70
- Q13R (p.Gln13Arg), TOPMed rs866392536, gnomAD rs866392536, REVEL 0.19, CADD 18.80
- P14R (p.Pro14Arg), rs2097911816, ClinGen CA370104566, ClinVar RCV001213183, Ensembl rs2097911816, AlphaMissense 0.22, MetaLR 0.22, Uncertain significance, not provided
- P14S (p.Pro14Ser), rs1191245918, ClinGen CA370104572, ClinVar RCV003707487, gnomAD rs1191245918, REVEL 0.17, CADD 18.10, Uncertain significance, not provided
- P15S (p.Pro15Ser), Ensembl rs2116821868, REVEL 0.32, CADD 19.90
- P16A (p.Pro16Ala), ExAC rs751297115, TOPMed rs751297115, gnomAD rs751297115, REVEL 0.43, CADD 20.40
- P16L (p.Pro16Leu), Ensembl rs2116821838, REVEL 0.45, CADD 22.90
- P16T (p.Pro16Thr), ExAC rs751297115, TOPMed rs751297115, gnomAD rs751297115, REVEL 0.45, CADD 22.50, Uncertain significance, Inborn genetic diseases
- P17L (p.Pro17Leu), TOPMed rs1261105602, gnomAD rs1261105602, REVEL 0.27, CADD 22.70
- P17S (p.Pro17Ser), Ensembl rs2116821820, REVEL 0.23, CADD 21.00
- P18A (p.Pro18Ala), TOPMed rs1323931123, gnomAD rs1323931123, REVEL 0.23, CADD 18.10, Uncertain significance
- P18H (p.Pro18His), ExAC rs758889240, gnomAD rs758889240, REVEL 0.38, CADD 22.50, Likely benign
- P18L (p.Pro18Leu), rs758889240, ClinGen CA4581845, ClinVar RCV002015640, ClinVar RCV003134337, REVEL 0.29, CADD 22.40, Conflicting interpretations, Inborn genetic diseases; not provided; Kleefstra syndrome 2
- P18S (p.Pro18Ser), rs1323931123, ClinGen CA370104514, ClinVar RCV002288241, ClinVar RCV005242214, REVEL 0.21, CADD 19.70, Uncertain significance, not provided; Kleefstra syndrome 2
- P18T (p.Pro18Thr), TOPMed rs1323931123, gnomAD rs1323931123, REVEL 0.28, CADD 19.20, Uncertain significance
- P19H (p.Pro19His), TOPMed rs1043931017, gnomAD rs1043931017, REVEL 0.41, CADD 24.10, Uncertain significance
- P19L (p.Pro19Leu), rs1043931017, ClinGen CA169240719, ClinVar RCV003886947, TOPMed rs1043931017, REVEL 0.42, CADD 22.60, Uncertain significance, not provided
- P19R (p.Pro19Arg), rs1043931017, ClinGen CA370104492, ClinVar RCV003404872, TOPMed rs1043931017, REVEL 0.45, CADD 23.00, Uncertain significance, not specified
- P19T (p.Pro19Thr), Ensembl rs2116821765, REVEL 0.50, CADD 21.60
- E20D (p.Glu20Asp), 1000Genomes rs191834730, ESP rs191834730, ExAC rs191834730, TOPMed rs191834730, Benign
- E20G (p.Glu20Gly), Ensembl rs2116821728
- E20R (p.Glu20Arg), NCI-TCGA Cosmic COSV1000, NCI-TCGA Cosmic COSV5140, Variant assessed as somatic; high impact.
- E21A (p.Glu21Ala), ExAC rs766413158, TOPMed rs766413158, gnomAD rs766413158, Benign
- E21D (p.Glu21Asp), Ensembl rs2097911586, REVEL 0.12, CADD 21.00
- E21G (p.Glu21Gly), rs766413158, ClinGen CA4581840, ClinVar RCV002976154, ExAC rs766413158, REVEL 0.17, CADD 23.40, Benign, not provided
- P22R (p.Pro22Arg), Ensembl rs2097911555, REVEL 0.41, CADD 23.10
- P22S (p.Pro22Ser), 1000Genomes rs568758596, ExAC rs568758596, TOPMed rs568758596, gnomAD rs568758596, REVEL 0.43, CADD 20.60, Uncertain significance, Inborn genetic diseases
- P22T (p.Pro22Thr), 1000Genomes rs568758596, ExAC rs568758596, TOPMed rs568758596, gnomAD rs568758596, REVEL 0.45, CADD 20.90
- G23A (p.Gly23Ala), Ensembl rs2116821658, REVEL 0.36, CADD 17.90
- G23E (p.Gly23Glu), Ensembl rs2116821658, REVEL 0.21, CADD 22.30
- G23R (p.Gly23Arg), gnomAD rs1470604537, REVEL 0.24, CADD 22.90
- A24D (p.Ala24Asp), ExAC rs768439100, TOPMed rs768439100, gnomAD rs768439100, REVEL 0.45, CADD 24.70, Likely benign
- A24G (p.Ala24Gly), ExAC rs768439100, TOPMed rs768439100, gnomAD rs768439100, Likely benign
- A24P (p.Ala24Pro), gnomAD rs1419470681, REVEL 0.40, CADD 24.10
- A24V (p.Ala24Val), rs768439100, ClinGen CA4581837, cosmic curated COSV10586, ClinVar RCV002766629, REVEL 0.32, CADD 24.50, Likely benign, not provided
- P25L (p.Pro25Leu), ExAC rs749087296, TOPMed rs749087296, gnomAD rs749087296, REVEL 0.37, CADD 24.10, Uncertain significance
- P25R (p.Pro25Arg), rs749087296, ClinGen CA4581836, ClinVar RCV002614637, ExAC rs749087296, REVEL 0.36, CADD 24.00, Uncertain significance, not provided
- A26G (p.Ala26Gly), TOPMed rs2097911468, gnomAD rs2097911468, REVEL 0.18, CADD 22.90
- A26P (p.Ala26Pro), Ensembl rs2116821600, REVEL 0.23, CADD 22.80
- A26S (p.Ala26Ser), Ensembl rs2116821600, REVEL 0.14, CADD 17.60
- A26T (p.Ala26Thr), Ensembl rs2116821600, REVEL 0.18, CADD 19.40
- A26V (p.Ala26Val), TOPMed rs2097911468, gnomAD rs2097911468, REVEL 0.22, CADD 23.00
- P27L (p.Pro27Leu), rs769792555, ClinGen CA4581834, ClinVar RCV003245570, ClinVar RCV003730493, REVEL 0.39, CADD 23.20, Uncertain significance, Inborn genetic diseases; not provided
- P27Q (p.Pro27Gln), ExAC rs769792555, TOPMed rs769792555, gnomAD rs769792555, REVEL 0.38, CADD 23.00, Uncertain significance
- P27R (p.Pro27Arg), rs769792555, ClinGen CA370104376, ClinVar RCV004409833, ExAC rs769792555, REVEL 0.40, CADD 23.00, Uncertain significance, Inborn genetic diseases
- P27S (p.Pro27Ser), NCI-TCGA Cosmic COSV1000, cosmic curated COSV10007, Ensembl rs2116821569, Variant assessed as somatic; moderate impact.
- P27T (p.Pro27Thr), Ensembl rs2116821569
- S28I (p.Ser28Ile), TOPMed rs1245067284, gnomAD rs1245067284, REVEL 0.34, CADD 23.90
- S28N (p.Ser28Asn), TOPMed rs1245067284, gnomAD rs1245067284, REVEL 0.25, CADD 23.40
- S28R (p.Ser28Arg), Ensembl rs1309606619, REVEL 0.32, CADD 23.70
- S28T (p.Ser28Thr), TOPMed rs1245067284, gnomAD rs1245067284
- P29H (p.Pro29His), TOPMed rs2097911322, REVEL 0.35, CADD 22.80, Uncertain significance
- P29L (p.Pro29Leu), rs2097911322, ClinGen CA370104347, ClinVar RCV001889919, TOPMed rs2097911322, REVEL 0.20, CADD 20.20, Uncertain significance, not provided
- P29S (p.Pro29Ser), Ensembl rs2097911335, REVEL 0.13, CADD 18.60
- A30E (p.Ala30Glu), Ensembl rs2116821500, REVEL 0.34, CADD 24.30
- A30G (p.Ala30Gly), Ensembl rs2116821500
- A30T (p.Ala30Thr), gnomAD rs1461694611, REVEL 0.34, CADD 23.30
- A31P (p.Ala31Pro), TOPMed rs1203336192, REVEL 0.38, CADD 23.00, Uncertain significance, Inborn genetic diseases
- A31S (p.Ala31Ser), TOPMed rs1203336192, REVEL 0.34, CADD 21.80
- A31T (p.Ala31Thr), TOPMed rs1203336192, REVEL 0.37, CADD 21.90
- A31V (p.Ala31Val), cosmic curated COSV51469, Ensembl rs2116821482, REVEL 0.32, CADD 21.70
- A32E (p.Ala32Glu), gnomAD rs1272275874, REVEL 0.29, CADD 22.40
- A32P (p.Ala32Pro), TOPMed rs1261470329, gnomAD rs1261470329, REVEL 0.27, CADD 19.10
- A32S (p.Ala32Ser), TOPMed rs1261470329, gnomAD rs1261470329, REVEL 0.20, CADD 15.90
- A32T (p.Ala32Thr), cosmic curated COSV10804, NCI-TCGA TCGA novel, TOPMed rs1261470329, gnomAD rs1261470329, REVEL 0.25, CADD 16.40, Variant assessed as somatic; moderate impact.
- A32V (p.Ala32Val), gnomAD rs1272275874, REVEL 0.26, CADD 20.80
- D33N (p.Asp33Asn), Ensembl rs2116821434, REVEL 0.43, CADD 24.70
- K34E (p.Lys34Glu), Ensembl rs2116821428
- K34N (p.Lys34Asn), Ensembl rs2116821421, REVEL 0.41, CADD 24.70
- R35G (p.Arg35Gly), Ensembl rs2116821414, REVEL 0.41, CADD 23.50
- R35I (p.Arg35Ile), NCI-TCGA Cosmic COSV5138, cosmic curated COSV51382, REVEL 0.52, CADD 24.70, Variant assessed as somatic; moderate impact.
- R35S (p.Arg35Ser), Ensembl rs2116821404
- P36S (p.Pro36Ser), gnomAD rs1212580747, REVEL 0.47, CADD 24.10
- R37G (p.Arg37Gly), TOPMed rs2097911235, REVEL 0.49, CADD 24.70
- R37P (p.Arg37Pro), gnomAD rs1270352611, REVEL 0.59, CADD 25.30
- R37W (p.Arg37Trp), cosmic curated COSV10605, TOPMed rs2097911235, REVEL 0.51, CADD 26.20
- G38A (p.Gly38Ala), Ensembl rs2116821343
- G38C (p.Gly38Cys), Ensembl rs2116821352, REVEL 0.55, CADD 25.10
- G38S (p.Gly38Ser), Ensembl rs2116821352, REVEL 0.53, CADD 24.60
- G38V (p.Gly38Val), Ensembl rs2116821343, REVEL 0.52, CADD 24.40
- R39P (p.Arg39Pro), gnomAD rs1312831387, REVEL 0.64, CADD 25.20
- R39W (p.Arg39Trp), TOPMed rs2097911172, gnomAD rs2097911172, REVEL 0.53, CADD 26.00
- P40A (p.Pro40Ala), Ensembl rs2116821295
- P40S (p.Pro40Ser), Ensembl rs2116821295, REVEL 0.53, CADD 24.30
- P40T (p.Pro40Thr), Ensembl rs2116821295, REVEL 0.52, CADD 24.00
- R41C (p.Arg41Cys), NCI-TCGA Cosmic COSV5143, cosmic curated COSV51435, NCI-TCGA Cosmic COSV9903, REVEL 0.50, CADD 26.20, Uncertain significance, not provided
- R41L (p.Arg41Leu), Ensembl rs867446641, REVEL 0.39, CADD 24.40
- R41S (p.Arg41Ser), gnomAD rs1354455950, REVEL 0.46, CADD 24.70
- K42* (p.Lys42Ter), Ensembl rs2116821283, CADD 35.00
- D43E (p.Asp43Glu), Ensembl rs2116821271, REVEL 0.40, CADD 24.40
- D43N (p.Asp43Asn), gnomAD rs1327515855, REVEL 0.38, CADD 25.10
- D43Y (p.Asp43Tyr), cosmic curated COSV51432, gnomAD rs1327515855, REVEL 0.50, CADD 25.20
- G44C (p.Gly44Cys), Ensembl rs867040886, REVEL 0.49, CADD 25.60
- G44D (p.Gly44Asp), Ensembl rs868067467, REVEL 0.46, CADD 24.60
- G44R (p.Gly44Arg), Ensembl rs867040886
- G44S (p.Gly44Ser), Ensembl rs867040886, REVEL 0.46, CADD 23.80
- G44V (p.Gly44Val), Ensembl rs868067467, REVEL 0.48, CADD 24.60
- A45S (p.Ala45Ser), gnomAD rs1411941788, REVEL 0.29, CADD 21.90
- A45T (p.Ala45Thr), gnomAD rs1411941788, REVEL 0.30, CADD 23.10
- S46F (p.Ser46Phe), Ensembl rs867190035, REVEL 0.43, CADD 25.70
- S46P (p.Ser46Pro), gnomAD rs2097911007, REVEL 0.36, CADD 25.40
- S46Y (p.Ser46Tyr), cosmic curated COSV51493, Ensembl rs867190035, REVEL 0.47, CADD 25.30
- P47H (p.Pro47His), gnomAD rs2097910947, REVEL 0.40, CADD 25.10
- P47L (p.Pro47Leu), gnomAD rs2097910947, REVEL 0.38, CADD 23.80
- P47S (p.Pro47Ser), TOPMed rs1163121070, gnomAD rs1163121070, REVEL 0.36, CADD 23.20
- P47T (p.Pro47Thr), TOPMed rs1163121070, gnomAD rs1163121070, REVEL 0.33, CADD 24.50
- F48S (p.Phe48Ser), cosmic curated COSV10726, Ensembl rs2116821200, REVEL 0.38, CADD 24.40
- Q49* (p.Gln49Ter), TOPMed rs2097910934, CADD 36.00
- Q49E (p.Gln49Glu), TOPMed rs2097910934
- Q49R (p.Gln49Arg), gnomAD rs1443044609, REVEL 0.27, CADD 21.40, Uncertain significance, Inborn genetic diseases
- R50G (p.Arg50Gly), gnomAD rs1387360850, REVEL 0.35, CADD 23.70
- R50I (p.Arg50Ile), TOPMed rs913978315, gnomAD rs913978315, REVEL 0.30, CADD 23.10
- R50K (p.Arg50Lys), rs913978315, ClinGen CA370104072, ClinVar RCV003318967, REVEL 0.29, CADD 16.90, Uncertain significance, not provided
- R50T (p.Arg50Thr), TOPMed rs913978315, gnomAD rs913978315, REVEL 0.23, CADD 19.90
- A51P (p.Ala51Pro), Ensembl rs2116821157
- A51T (p.Ala51Thr), NCI-TCGA Cosmic COSV5143, Ensembl rs2116821157, REVEL 0.13, CADD 20.10, Variant assessed as somatic; moderate impact.
- A51V (p.Ala51Val), gnomAD rs1232164733, REVEL 0.17, CADD 21.00
- R52G (p.Arg52Gly), gnomAD rs1202370478, REVEL 0.23, CADD 23.60
- R52K (p.Arg52Lys), Ensembl rs2116821122, REVEL 0.18, CADD 20.40
- K53E (p.Lys53Glu), Ensembl rs2116821114, REVEL 0.23, CADD 23.30
- K53N (p.Lys53Asn), cosmic curated COSV51422, Ensembl rs2097910830, REVEL 0.21, CADD 23.20
- K54N (p.Lys54Asn), Ensembl rs2097171791, REVEL 0.27, CADD 22.30
- P55A (p.Pro55Ala), gnomAD rs2097171770, REVEL 0.32, CADD 23.10
- P55H (p.Pro55His), TOPMed rs987209809, REVEL 0.37, CADD 23.20
- P55L (p.Pro55Leu), TOPMed rs987209809, REVEL 0.37, CADD 23.30
- P55R (p.Pro55Arg), TOPMed rs987209809
- P55S (p.Pro55Ser), gnomAD rs2097171770, REVEL 0.37, CADD 22.10
- P55T (p.Pro55Thr), gnomAD rs2097171770, REVEL 0.37, CADD 23.90
- R56* (p.Arg56Ter), rs1283285486, NCI-TCGA Cosmic COSV5128, cosmic curated COSV51288, TOPMed rs1283285486, CADD 37.00, Variant assessed as somatic; high impact.
- R56G (p.Arg56Gly), TOPMed rs1283285486, gnomAD rs1283285486, REVEL 0.39, CADD 22.90
- R56L (p.Arg56Leu), gnomAD rs1403418496, REVEL 0.39, CADD 25.40, Likely benign
- R56P (p.Arg56Pro), gnomAD rs1403418496, Likely benign
- R56Q (p.Arg56Gln), rs1403418496, ClinGen CA370197785, NCI-TCGA Cosmic COSV5134, cosmic curated COSV51343, REVEL 0.27, CADD 25.10, Likely benign, not provided
Public KMT2C analysis runs
- KMT2C analysis run — KMT2C (15,046 variants) — completed 2026-08-19